HTT and Huntington disease: Preclinical trials on FUS-mediated BBB opening in HD models consistently demonstrate promising outcomes [32, 65, 66], including increased brain concentrations of therapeutic agents, along with significant reductions in mHTT mRNA levels and abnormal cytoplasmic HTT protein aggregates.